Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib + Pembrolizumab in Advanced TNBC/TN-IBC
NCT03184558Phase 2Terminated
- Sponsor
- BerGenBio ASA
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of bemcentinib in triple-negative breast cancer (TNBC), inflammatory breast cancer (IBC), sponsored by BerGenBio ASA. Started Jul 2017; status: terminated.
02
Drugs
bemcentinib
03
Conditions
triple-negative breast cancer (TNBC)inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03184558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184558.